Soliris (eculizumab) is a monoclonal antibody. It works by targeting the complement protein C5. It is used to treat several rare, life-threatening, and complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD). Soliris has transformed outcomes in patients with uncontrolled complement activity. It helps improve both survival and quality of life (QoL).
Soliris has been approved by regulatory authorities such as the U.S. FDA and the European Medicines Agency (EMA). However, Soliris in India has not yet been approved. Despite this, patients in India who urgently need this therapeutic drug can access it through legal provisions like the Named Patient Program (NPP). The program allows access to unapproved or unavailable medicines.
Soliris (Eculizumab): Quick Overview
- Generic Name: Eculizumab
- Brand Name: Soliris
- Type: Monoclonal antibody (Complement C5 inhibitor)
- Form: Intravenous (IV) injection
- FDA Status: Approved for PNH, NMOSD, aHUS, gMG
- Indication: Soliris is a complement inhibitor. It is used for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. It is also used for atypical hemolytic uremic syndrome (aHUS) to block complement-mediated thrombotic microangiopathy.
Availability of Soliris in India:
Soliris has not yet received commercial marketing authorization in India and is therefore not available through domestic hospital pharmacies. However, Indian Pharma Network (IPN) helps eligible patients gain access to Soliris through legal Named Patient Import channels. This regulatory provision permits the import of life-saving medicines on a case-by-case basis for patients with valid prescriptions who have exhausted standard local treatment options.
Indian Pharma Network (IPN): Trusted Importer & Supplier of Soliris in India
Indian Pharma Network (IPN) is a leading pharmaceutical access company in India. We specialize in sourcing and supplying hard-to-access medicines for rare diseases and advanced therapies under legal frameworks. IPN supports hospitals, physicians, and patients in accessing Soliris and other essential medicines with a transparent, compliant, and patient-first approach.
Why Choose IPN?
- Recognized Soliris importer in India under the CDSCO guidelines
- Experienced in Named Patient Programs and rare disease access
- Seamless documentation and import permissions
- Cold-chain and quality-controlled logistics
- Supply to patients, doctors, hospitals, and clinics
- Transparent import process and advisory support
How to Import Soliris Injection in India through IPN?
- Step-by-Step Process: Medical Prescription: A specialist doctor must prescribe this therapeutic drug to an eligible patient.
- Consent & Medical Documents: Submit diagnosis reports, patient details, and treatment history.
- CDSCO & DGFT Approvals: IPN initiates and obtains regulatory approvals for patient-specific import.
- Procurement: Soliris is sourced from approved and licensed suppliers across the U.S., Europe, and other markets.
- Delivery: IPN ensures temperature-controlled delivery to the treating hospital or the patient’s home within 7 to 10 business days.
Who Can Request Soliris?
- People living with PNH, gMG, aHUS, or NMOSD.
- Specialty hospitals that treat complement-related disorders
- Hematologists, neurologists, and other rare disease experts
- Institutions running compassionate use or clinical programs
Alternate Therapeutic Options for Complement-Mediated Disorders:
Though Soliris is often first in line, some patients may benefit from other approved drugs or fresh therapies. Choices the FDA currently backs include:
Efgartigimod (Vyvgart): Approved for gMG (acts via IgG reduction)
Plasma Exchange or Supportive Care: In select acute scenarios
Ultomiris (Ravulizumab): A longer-acting C5 inhibitor for PNH and aHUS
Rituximab: Off-label for certain NMOSD patients
Indian Pharma Network (IPN) can help obtain any of these medicines depending on the diagnosis and clinical requirement.
Need Help Accessing Soliris in India?
Whether you’re a clinician, patient, caregiver, or hospital unit in need of Soliris, Indian Pharma Network (IPN) stands by you. With decades of experience handling requests for rare, lifesaving medicines, we walk you through each step, from paperwork to doorstep delivery. Our goal is simple: no eligible person should miss treatment because a medicine is hard to find. Submit your request today for complete support.
Disclaimer: This blog is for informational purposes only. Soliris must be administered under the guidance of a certified healthcare professional. All medicines imported through IPN are handled under CDSCO and DGFT regulations.
Is Soliris available in India?
No. Soliris is not yet available in India. However, patients can import it legally under the CDSCO’s Named Patient Program (NPP) via authorized importers like us.
Who is the best Soliris supplier in India?
Indian Pharma Network (IPN) is a leading Soliris importer and supplier in India. We facilitate timely access to this therapeutic drug for those patients who are eligible for this medicine.
What is the cost of Soliris in India?
The cost of Soliris in India generally depends on several factors. For an accurate quotation, please contact us with a valid prescription and patient information.
How long does it take to import Soliris in India?
After the completion of documentation and regulatory approvals, delivery of this medicine generally takes 7 to 10 working days through our cold-chain-enabled supply network.
Is Soliris approved by global regulators?
Yes. Soliris is FDA and EMA-approved for treating PNH, aHUS, gMG, and NMOSD. It is one of the most effective complement inhibitors available today.
Can IPN help with the bulk supply of Soliris for hospitals?
Yes. IPN coordinates directly with hospitals and specialists for bulk imports under compliant supply programs for rare disease care.
